Zymeworks (Nasdaq: ZYME), a clinical-stage biotech developing antibody-based therapies for cancer and immune diseases, has appointed Sabeen Mekan as senior vice president of clinical development.
Dr Mekan brings 18 years of experience in hematology and oncology, with prior leadership roles at firms including Gilead Sciences (Nasdaq: GILD), where she oversaw lung and gastrointestinal cancer programs.
The move aligns with the company’s broader strategy to diversify into autoimmune, inflammatory, and hematologic conditions.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze